ModerateCaution
Berberine
Berberine affects glucose while GHRP-6 may worsen glucose tolerance and increase appetite.
Recommendation: Do not use berberine to compensate for unapproved peptide-related glucose effects; monitor medically.
GHRP-6
Peptide ·Insufficient evidence ·Reviewed May 2026
GHRP-6 is a synthetic hexapeptide growth hormone secretagogue that activates the ghrelin or growth hormone secretagogue receptor and can trigger GH release and strong appetite stimulation. It is not FDA-approved for human use, is generally sold as a research chemical, and long-term safety or body-composition outcome evidence in healthy adults is limited. Risks include hunger, glucose changes, edema, cortisol or prolactin effects, injection risks, and WADA-prohibited status for tested athletes.
What it's good for
- Acutely stimulates GH release in research settings
- Strongly stimulates appetite
- May increase IGF-1 indirectly with repeated GH-axis activation
- No approved wellness or performance use
What to watch for
- Marked hunger
- Water retention
- Tingling or numbness
- Active cancer or unexplained tumor risk
- Pregnancy and breastfeeding
The bottom line
Evidence rating insufficient. Most-documented uses: acutely stimulates gh release in research settings, strongly stimulates appetite, may increase igf-1 indirectly with repeated gh-axis activation. 3 sources indexed (1998–2025), with 3 interaction records on file.
The science
How it works, mechanistically.
Core mechanism
GHRP-6 activates GHS-R1a receptors in the pituitary and hypothalamus, amplifying GH pulses through a pathway distinct from GHRH but partly dependent on endogenous GHRH tone. Ghrelin receptor activation also stimulates appetite and may affect gastric motility, glucose regulation, cortisol, and prolactin. Repeated exposure may produce desensitization and does not establish durable clinical benefit.1,2
Class
Research GH secretagogue and ghrelin receptor agonist
Found in food
None
Low-status signs
No GHRP-6 deficiency exists
Dosing
Dosing & protocol.
Common range
No FDA-approved human dose; published studies used supervised single-dose or short research protocols
Recommended form
Not recommended as a supplement; research or clinical study use only
Peptide requires parenteral administration in studies. Nonsterile or research-grade injection is unsafe.
Forms
Forms & what to buy.
Ranked by evidence and value.
Lyophilized Research Peptide Recommended
Not an approved drug product and not appropriate for human injection. Sterility and identity cannot be assumed from research vendors.
Clinical Research Injectable
Used only under approved research protocols. Requires medical oversight.
Cost
What it actually costs.
Real-world pricing across three quality tiers. Assumes Research peptide vial.
BudgetBest value
$45 /mo
$1.50 per dose
Mid
$120 /mo
$4.00 per dose
Premium
$300 /mo
$10.00 per dose
Prices reflect research-market products, which are not appropriate for human use. Updated 2026-06-04.
Goals
Goal-based dosing.
GH Stimulation Research
Dose: Protocol-specific; no approved consumer dose3
Timing: Research protocol only
Acute GH release does not prove long-term benefit.
Appetite Stimulation
Dose: No approved dose3
Timing: Not applicable
Appetite stimulation is a pharmacologic effect and can worsen weight or glucose control.
Body Composition or Anti-Aging
Dose: No approved dose
Timing: Not applicable
Long-term safety and efficacy are not established.
Lab work
Markers to track.
What to test, the optimal window inside the conventional range, and how long a response takes.
Insulin-Like Growth Factor 1 IGF-1
May increase if repeated GH stimulation occurs, but response is variable.1,2
Optimal
80–250 ng/mL
Conventional
50–300 ng/mL
Responds in
4-8 weeks if clinically monitored
50optimal300
Do not use IGF-1 monitoring to justify unsupervised research peptide use.
Fasting glucoseHbA1cProlactin
Fasting Glucose Glucose
GH secretagogues can worsen glucose tolerance in susceptible users.1
Optimal
70–90 mg/dL
Conventional
70–99 mg/dL
Responds in
Baseline and follow-up if medically supervised
70optimal99
Monitor closely in insulin resistance or diabetes.
HbA1cFasting insulinIGF-1
Why people use it
Symptoms it's matched to.
Where this appears in the symptom-to-supplement map, ranked by relevance.
Low appetite
22% relevance
Ghrelin receptor activation can stimulate hunger, but it is not approved for appetite treatment.
DigestiveInsufficient evidenceNot recommended
Use medical evaluation for unexplained appetite loss.
Low IGF-1 on labs
20% relevance
Can acutely stimulate GH and potentially IGF-1, but not approved for treatment.
HormoneInsufficient evidenceResearch only
Needs endocrinology evaluation.
Poor muscle recovery
8% relevance
Body composition claims are extrapolated from GH-axis effects, not proven outcomes.
AthleticInsufficient evidenceNot recommended
WADA-prohibited and not FDA-approved.
Safety
Full safety detail.
Side effects
- Marked hunger
- Water retention
- Tingling or numbness
- Headache
- Flushing
- Injection-site reaction
- Glucose intolerance
- Possible cortisol or prolactin elevation
Contraindications
- Active cancer or unexplained tumor risk
- Pregnancy and breastfeeding
- Diabetes or uncontrolled glucose intolerance without specialist care
- History of pituitary disease without endocrinology supervision
- Competitive athletes subject to anti-doping rules1
- Non-FDA-approved human use and research-grade product injection2
Interactions
Interaction records.
ModerateCaution
Alpha-Lipoic Acid
Alpha-lipoic acid may lower glucose while GHRP-6 can alter glucose and hunger signals.
Recommendation: Avoid unsupervised metabolic stacking; monitor glucose if under medical study.
InfoCaution
Creatine
Creatine-related water weight can mask edema or rapid weight gain from GH secretagogue effects.
Recommendation: Track edema, blood pressure, numbness, and glucose rather than relying on scale weight alone.
Sources
Sources, by evidence tier.
Numbered references. Citations throughout the page link here.
Reference material
3- 1The 2026 Prohibited List: International StandardNeeds sourceNo linkWorld Anti-Doping Agency · World Anti-Doping Agency · 2025
Growth hormone secretagogues and GHRPs are prohibited for athletes under S2 categories.
- 2Pharmacokinetic study of Growth Hormone-Releasing Peptide 6 (GHRP-6) in nine male healthy volunteersNeeds sourceNo linkCabrales A et al. · European Journal of Pharmaceutical Sciences · 2013
Single intravenous bolus pharmacokinetics were studied in nine healthy men.
- 3Growth hormone (GH)-releasing peptide-6 requires endogenous hypothalamic GH-releasing hormone for maximal GH stimulationNeeds sourceNo linkRussell-Jones DL et al. · Journal of Clinical Endocrinology and Metabolism · 1998
GHRH antagonism blunted GH response to GHRP-6, showing pathway interaction.
Keep exploring
Deep dives & adjacent profiles.
This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.
Use this with your stack
GHRP-6 in NutriStack.
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.